480
Participants
Start Date
September 8, 2014
Primary Completion Date
May 5, 2016
Study Completion Date
March 22, 2017
Placebo
Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
Golimumab
Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
Glendale
Mesa
Huntington Beach
Lakewood
Granger
Indianapolis
Monroe
Tupelo
St Louis
Orchard Park
Salisbury
Duncansville
Austin
Daw Park
Maroochydore
Grodno
Homyel
Minsk
Vitebsk
St. John's
Waterloo
Burlington
Bad Doberan
Berlin
Cologne
Erfurt
Hamburg
Ratingen
Zerbst
Balatonfüred
Budapest
Debrecen
Hévíz
Kistarcsa
Nyíregyháza
Szombathely
Alytus
Kaunas
Klaipėda
Šiauliai
Vilnius
Bydgoszcz
Bytom
Częstochowa
Krakow
Lublin
Nadarzyn
Nowa Sól
Poznan
Warsaw
Wroclaw
Bucharest
Constanța
Iași
Ploieşti
Kemerovo
Korolyov
Krasnoyarsk
Kursk
Moscow
Novosibirsk
Orenburg
Petrozavodsk
Ryazan
Saint Petersburg
Saratov
Tomsk
Tver'
Ulyanovsk
Vladimir
Yaroslavl
Córdoba
Getafe
Seville
Chernihiv
Dnipropetrovsk
Kharkiv
Khmelnitsky
Kryvyi Rih
Kyiv
Lviv
Odesa
Poltava
Sumy
Ternopil
Uzhhorod
Vinnytsia
Zaporizhzhia
Janssen Research & Development, LLC
INDUSTRY